Christopher Yea - 17 May 2022 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
Chief Development Officer
Signature
/s/ Benjamin L. Palleiko, Attorney-in-Fact
Issuer symbol
KALV
Transactions as of
17 May 2022
Transactions value $
$0
Form type
4
Filing time
19 May 2022, 16:57:18 UTC
Previous filing
03 Nov 2021
Next filing
19 Aug 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALV Employee Stock Option (Right to Buy) Award $0 +18.9K $0.00 18.9K 17 May 2022 Common Stock 18.9K $9.28 Direct F1
transaction KALV Restricted Stock Units Award $0 +28.4K $0.00 28.4K 17 May 2022 Common Stock 28.4K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests over a 4 year period: 1/48th on June 17,2022, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F3 1/16th of the total RSUs subject to the Award shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, subject to continued service through each vesting date.